Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150632 | 0.83 | ACHE (0.58) | ACHEKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL6917132 | 0.83 | ACHE (0.54) | ACHEKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL5953419 | 0.79 | ACHE (0.57) | ACHEKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL5953118 | 0.78 | ACHE (0.49) | ACHEKDM4ECYP1A2CYP2C19HTT | |
| SCHEMBL5952132 | 0.76 | ACHE (0.54) | ACHEKDM4EALDH1A1HPGDGAA | |
| SCHEMBL3150892 | 0.76 | ACHE (0.54) | ACHEKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5952137 | 0.74 | ACHE (0.64) | ACHEKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL5953541 | 0.73 | HTR1A (0.52) | ACHECYP2C19CYP2C9 | |
| SCHEMBL3154249 | 0.73 | ACHE (0.54) | ACHEMAPT | |
| SCHEMBL1825039 | 0.72 | ACHE (0.49) | ACHEANPEPMAPTCYP19A1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5861522-A | Production of bridged metallocene complexes and intermediates therefor | ALBEMARLE CORPORATION (US) | 1999-01-19 | — | — | US | claimed |
| EP-0854876-A2 | PRODUCTION OF BRIDGED METALLOCENE COMPLEXES AND INTERMEDIATES THEREFOR | ALBEMARLE CORPORATION (US) | 1998-07-29 | — | — | EP | claimed |
| US-5710299-A | Production of bridged metallocene complexes and intermediates therefor | ALBEMARLE CORPORATION (US) | 1998-01-20 | — | — | US | claimed |
| WO-1997049712-A2 | PRODUCTION OF BRIDGED METALLOCENE COMPLEXES AND INTERMEDIATES THEREFOR | ALBEMARLE CORPORATION (US) | 1997-12-31 | — | — | WO | claimed |
| US-20200062874-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | PETROCHINA COMPANY LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20180079843-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | PETROCHINA COMPANY LIMITED (CN) | 2018-03-22 | — | — | US | disclosed |
| US-6245944-B1 | REACTING SUBSTITUTED NAPHTHALENE WITH METHACRYLOYL HALIDE IN PRESENCE OF FRIEDEL-CRAFTS CATALYST IN CHLORINATED HYDROCARBON SOLVENT AT TEMPERATURES BETWEEN-30 AND 0 DEGREES C. IN ONE STEP TO YIELD SUBSTITUTED INDANONE | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| EP-0906260-B1 | PROCESS FOR PRODUCING SUBSTITUTED INDANONES | BASF AG (DE) | 2001-01-03 | — | — | EP | disclosed |
| US-5942636-A | Process of preparing 2-alkyl-2,3-dihydro-1H-benz e!indene-1-one derivatives | AKZO NOBEL N.V. (NL) | 1999-08-24 | — | — | US | disclosed |
| EP-0906260-A1 | PROCESS FOR PRODUCING SUBSTITUTED INDANONES | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-07 | — | — | EP | disclosed |
| US-5861522-A | Production of bridged metallocene complexes and intermediates therefor | ALBEMARLE CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| EP-0856506-A1 | Process of preparing 2-alkyl-2,3-dihydro-1H-benz(e)indene-1-one derivatives | Akzo Nobel N.V. (NL) | 1998-08-05 | — | — | EP | disclosed |
| EP-0854876-A2 | PRODUCTION OF BRIDGED METALLOCENE COMPLEXES AND INTERMEDIATES THEREFOR | ALBEMARLE CORPORATION (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5710299-A | Production of bridged metallocene complexes and intermediates therefor | ALBEMARLE CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1997049661-A1 | PROCESS FOR PRODUCING SUBSTITUTED INDANONES | BASF AKTIENGESELLSCHAFT (DE) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049712-A2 | PRODUCTION OF BRIDGED METALLOCENE COMPLEXES AND INTERMEDIATES THEREFOR | ALBEMARLE CORPORATION (US) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079843-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | NR4A2, NR4A1, ORC3 | ACHE 3615/4885KDM4E 3552/4885ALDH1A1 3715/4885 |
| US-20200062874-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | ORC3, ORMDL3, OR51E2 | ACHE 3485/4885KDM4E 3517/4885ALDH1A1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.